New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Jasper Therapeutics, Inc. (JSPR) vs Tvardi Therapeutics, Inc. (TVRD)

Jasper Therapeutics, Inc. and Tvardi Therapeutics, Inc. are both Biotechnology companies. Jasper Therapeutics, Inc. and Tvardi Therapeutics, Inc. are of similar size ($12.6M and $11.9M). Across the 8 metrics below, Tvardi Therapeutics, Inc. leads on 5 and Jasper Therapeutics, Inc. on 3.

Valuation

Metric JSPR TVRD Biotechnology median
P/E n/m n/m 8.49
P/S — 1.65 8.56
P/B n/m 0.81 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.70 0.35 0.69
EV/Sales — (1.29) 8.00
Earnings yield (1,704.93%) (271.11%) (35.81%)
Free cash flow yield (521.45%) (216.75%) (25.41%)

Profitability

Metric JSPR TVRD Biotechnology median
Gross margin — 146.85% 70.18%
Operating margin — (36.92%) 0.00%
Net margin — (459.31%) 0.00%
Free cash flow margin — 58.90% 0.00%
Return on equity 244.79% (123.08%) (51.58%)
Return on assets (153.74%) (85.24%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric JSPR TVRD Biotechnology median
Revenue growth (TTM) — (55.30%) 7.20%
EPS growth (last fiscal year) 19.22% 71.45% 29.04%
Revenue growth, 5-year CAGR — (18.53%) 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric JSPR TVRD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.59 2.86 4.79
Net debt to EBITDA 0.35 1.15 1.01

Dividend

Metric JSPR TVRD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric JSPR TVRD Biotechnology median
Market cap 11.92m 12.64m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack